Jefferies Remains a Buy on United Therapeutics (UTHR)

Jefferies analyst Roger Song maintained a Buy rating on United Therapeutics today and set a price target of $733.00.

Meet Samuel – Your Personal Investing Prophet

• Start a conversation with TipRanks’ trusted, data-backed investment intelligence
• Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds

Song covers the Healthcare sector, focusing on stocks such as United Therapeutics, Oruka Therapeutics, and Cabaletta Bio. According to TipRanks, Song has an average return of 0.6% and a 40.32% success rate on recommended stocks.

In addition to Jefferies, United Therapeutics also received a Buy from TD Cowen’s Joseph Thome in a report issued on May 17. However, on May 11, Oppenheimer assigned a Hold rating to United Therapeutics (NASDAQ: UTHR).

Based on United Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $781.5 million and a net profit of $274.9 million. In comparison, last year the company earned a revenue of $794.4 million and had a net profit of $322.2 million

Based on the recent corporate insider activity of 391 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of UTHR in relation to earlier this year. Earlier this month, Nilda Mesa, a Director at UTHR sold 258.00 shares for a total of $150,137.94.